Table 3.
Type II ANOVA tables for aim 2: logistic mixed effects for presence of clinically-significant depressive symptoms by diagnosis
| Χ2 | df | p Value | Effect size (RESI) | |
|---|---|---|---|---|
| Main effects for age-diagnosis interaction model | ||||
| Diagnosis | 3.870 | 1 | 0.049 | 0.110 |
| Age (nonlinear) | 10.233 | 2 | 0.006 | 0.186 |
| Peak COVID Year | 0.001 | 1 | 0.971 | 0.000 |
| Sex | 6.092 | 1 | 0.014 | 0.147 |
| Medication | 1.524 | 1 | 0.217 | 0.047 |
| Diagnosis:age (nonlinear) | 11.386 | 2 | 0.003 | 0.199 |
| Main effects for GB stage-diagnosis interaction model | ||||
| Diagnosis | 3.469 | 1 | 0.063 | 0.103 |
| G/B development stage (nonlinear) | 5.503 | 2 | 0.064 | 0.123 |
| Peak COVID year | 0.267 | 1 | 0.606 | 0.000 |
| Sex | 10.963 | 1 | 0.001 | 0.207 |
| Medication | 3.876 | 1 | 0.049 | 0.111 |
| Diagnosis:G/B development stage (nonlinear) | 8.517 | 2 | 0.014 | 0.167 |
| Main effects for PH stage-diagnosis interaction model | ||||
| Diagnosis | 3.892 | 1 | 0.049 | 0.111 |
| PH development stage (nonlinear) | 6.112 | 2 | 0.047 | 0.133 |
| Peak COVID Year | 0.604 | 1 | 0.437 | 0.000 |
| Sex | 11.005 | 1 | 0.001 | 0.207 |
| Medication | 4.128 | 1 | 0.042 | 0.116 |
| Diagnosis:PH development stage (nonlinear) | 5.72 | 2 | 0.057 | 0.126 |
Peak COVID Year defined as 0 = exam not during peak COVID or 1 = exam occurred during peak COVID
G/B genital/breast, PH pubic hair